Touro Scholar
NYMC Faculty Publications

Faculty

5-1-2017

Management of Hypertension in Patients Undergoing Surgery
Wilbert S. Aronow
New York Medical College

Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs
Part of the Cardiology Commons, and the Surgery Commons

Recommended Citation
Aronow, W. S. (2017). Management of Hypertension in Patients Undergoing Surgery. Annals of
Translational Medicine, 5 (10), 227. https://doi.org/10.21037/atm.2017.03.54

This Editorial is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for
inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information,
please contact touro.scholar@touro.edu.

Editorial

Page 1 of 3

Management of hypertension in patients undergoing surgery
Wilbert S. Aronow
Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
Correspondence to: Wilbert S. Aronow, MD, FACC, FAHA. Professor of Medicine, Cardiology Division, Westchester Medical Center and New York
Medical College, Macy Pavilion, Room 141, Valhalla, NY 10595, USA. Email: wsaronow@aol.com.
Submitted Feb 05, 2017. Accepted for publication Feb 07, 2017.
doi: 10.21037/atm.2017.03.54
View this article at: http://dx.doi.org/10.21037/atm.2017.03.54

Hypertension is a major risk factor for causing coronary
events, stroke, heart failure, peripheral arterial disease,
dissecting aneurysm, chronic kidney disease, and
mortality (1-4). Hypertension in the perioperative and
postoperative period increases cardiovascular events,
cerebrovascular events, bleeding, and mortality and should
be controlled prior to major elective noncardiac surgery and
cardiac surgery (5-7). The higher the blood pressure, the
greater the risk. A systematic review and meta-analysis of
30 observational studies found that hypertension increased
perioperative cardiovascular complications by 35% (8).
As much as 25% of patients having major non-cardiac
surgery have perioperative hypertension (9). As much as
80% of patients having cardiac surgery have perioperative
hypertension (6,7). Hypertensive comorbidities associated
with adverse perioperative outcomes include occult
coronary artery disease (Q waves on the electrocardiogram),
heart failure, left ventricular hypertrophy, serum creatinine
higher than 2.0 mg/dL, and cerebrovascular disease (10).
Hypertension is the commonest avoidable medical
reason for postponing surgery (9). However, there are no
universally accepted guidelines stating the level of blood
pressure at which elective surgery should be cancelled (9).
Increased complications including myocardial infarction,
myocardial ischemia, dysrhythmias, cerebrovascular events,
and renal failure have been reported if the preoperative
diastolic blood pressure is 110 mmHg or higher (11). It has
been recommended to cancel elective surgery if the systolic
blood pressure is 180 mmHg or higher or if the diastolic
blood pressure is 110 mmHg or higher (8,10).
The frequency of acute postoperative hypertension
has been reported to be between 9% to 64% in patients
undergoing carotid endarterectomy, 22% to 54% in
patients undergoing cardiac surgery, 20% in patients
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undergoing elective noncardiac surgery, 33% to 75% in
patients undergoing abdominal aortic surgery, and 57% to
91% in patients undergoing intracranial neurosurgery (7).
Preoperative hypertension is the most determinant in the
development of postoperative hypertension in patients
following carotid endarterectomy (12). In a study of 253
carotid endarterectomies, postoperative hypertension was
associated with an increase in neurologic morbidity and
mortality (12). In a study of 2,069 patients undergoing
elective coronary artery bypass grafting surgery, 29.6%
had preoperative isolated systolic hypertension (13). The
patients with preoperative isolated systolic hypertension had
a 40% increase in perioperative cardiovascular events (13).
Drugs used for the treatment of hypertension depends
on associated comorbidities (1-4). For example, patients
with coronary artery disease should be treated with beta
blockers and angiotensin converting enzyme inhibitors or
angiotensin receptor blockers plus thiazide-or thiazidelike diuretics or calcium channel blockers if additional
antihypertensive medication is required (1-4,14). The
blood pressure treatment goal I recommend depends on
the comorbidities (15). There are no randomized clinical
trial data showing what the optimal blood pressure should
be at the time of surgery. On the basis of the available data,
I favor a blood pressure of less than 130/80 mmHg at the
time of surgery, especially in older persons (16).
The 2014 American College of Cardiology/American
Heart Association guideline on perioperative cardiovascular
evaluation and management of patients undergoing
noncardiac surgery recommend perioperative beta blocker
therapy in patients being treated with beta blockers and
starting beta blockers in patients with intermediate- or
high-risk preoperative tests or with a Revised Cardiac Risk
index of 3 or higher (17). Beta blockers should be initiated
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more than 1 day prior to surgery (17). Beta blockers should
not be started on the day of noncardiac surgery because of
data from the Perioperative Ischemic Evaluation (POISE)
trial (17,18). The 2014 American College of Cardiology
guidelines also state that it is reasonable to continue
angiotensin -converting enzyme inhibitors or angiotensin
receptor blockers perioperatively (17). Use of angiotensinconverting enzyme inhibitors was not associated with
respiratory complications or mortality after noncardiac
surgery (19).
Numerous studies have demonstrated that perioperative
use of beta blockers in patients undergoing major noncardiac
surgery reduces 30-day and 1-year mortality (20-24). In
711 peripheral vascular surgery patients, perioperative beta
blocker withdrawal was associated with a 2.7 times higher
1-year mortality while continuation of beta blockers reduced
1-year mortality 60% (24). In another study of 140 patients
undergoing vascular surgery receiving perioperative beta
blockers, 8 patients discontinued them postoperatively (25).
Postoperative mortality was 50% in the patients who stopped
beta blockers versus 1.5% in the patients who continued
beta blockers (25).
Commonly used drugs for management of postoperative
surgical hypertension include administration of
intravenous nitroglycerin, sodium nitroprusside, beta
blockers, hydralazine, and calcium channel blockers
including clevidipine (26,27). Clevidipine is a rapid-acting,
dihydropyridine L-type calcium channel blocker with a
half-life of about 1 minute that reduces arterial pressure by
direct arterial vasodilation with selective action on arteriolar
resistance vessels and does not cause reflex tachycardia
and tachyphylaxis (27). Its favorable pharmacodynamic
and pharmacokinetic properties cause clevidipine to be
an effective and safe drug for treating acute perioperative
hypertension (26,27). A systematic review and meta-analysis
concluded that clevidipine was the drug of choice for the
management of acute postoperative hypertension (26). Three
prospective, randomized, open-label, parallel comparison
studies compared use of clevidipine to nitroglycerin or
sodium nitroprusside perioperatively or to nicardipine
postoperatively for acute hypertension treatment in 1,512
cardiac surgery patients (27). There was no difference in
the incidence of myocardial infarction, stroke, or renal
dysfunction between clevidipine and the other three
drugs used (27). There was no difference in mortality
between clevidipine, nitroglycerin, and nicardipine.
Mortality, however, was higher in sodium nitroprussidetreated patients than in clevidipine-treated patients (27).
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Clevidipine was also more effective than nitroglycerin or
sodium nitroprusside in maintaining blood pressure within
the prespecified blood pressure range and had fewer blood
pressure excursions beyond these blood pressure limits than
nicardipine (27). Patients with intraoperative hypertension
should be treated with intravenous medications until they
can resume oral medications.
Antihypertensive drug therapy should not be stopped
abruptly (25,28,29). Withdrawal syndromes have been
reported after abrupt cessation of beta blockers, clonidine
hydrochloride, methyldopa, guanabenz, and bethanidine
sulfate (28). Accelerated angina pectoris, myocardial
infarction, or ventricular arrhythmias may occur in patients
with coronary artery disease after abrupt cessation of
beta blockers (25,28,29). Abrupt cessation of clonidine
hydrochloride, methyldopa, reserpine, and guanfacine may
cause a hyperadrenergic state with severe hypertension,
tachycardia, anxiety, and sweating (28,29).
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